ACT-AD has submitted a letter to the U.S. House and Senate Appropriations Subcommittees on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies requesting a $120 million increase in appropriated funding for the U.S. Food and Drug Administration (FDA) for fiscal year 2017. This would increase funding from $2.73 billion in FY16 to $2.85 billion in FY17.
The letter notes:
In recent years the FDA has undertaken crucial, but resource-intensive, initiatives for the timely review of Alzheimer’s disease therapies. These activities include the release of draft guidance for industry detailing FDA’s current thinking on early Alzheimer’s disease therapeutic development. The agency also has increased its participation in national and international meetings with patient advocates, researchers, and industry focused on improving Alzheimer’s disease clinical trials. It is essential that the FDA has the resources that enable its engagement with researchers, patients, and caregivers so that it can incorporate emerging insights and cutting edge discoveries into the agency’s regulation of therapies. The pace of innovation is rapidly increasing, along with the complexity of therapeutic applications. If the United States is to be at the forefront of medical innovation, the FDA must be provided with the financial support to facilitate nimble and up-to-date regulatory approaches.
You can read the entire letter here.